

DEAR FELLOW SHAREHOLDERS

Solos Endoscopy, Inc. has been at the forefront of breakthrough medical instruments and technologies for the screening, diagnosis, treatment and management of medical conditions for over 20 years. We market over 200 items to the endoscopic market and are continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques.

OUR MISSION

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions.

As filed in the Company's financials, the net loss for the fiscal year ended December 31, 2010 was \$1,192,481. The net loss as reported in the financials decreased by \$1,118,724, as compared to the fiscal year ended December 31, 2009, in which Solos reported a net loss of \$2,311,205. Revenues for the twelve months ended December 31, 2010 increased to \$429,473 versus \$421,882 for the period ended December 31, 2009, a gain of \$7,591. Gross profit increased by \$100,400 for the fiscal year 2010 versus 2009 due to product purchases made in the last three quarters of 2010 when the value of the dollar increased against the Euro. The Company's balance sheet included total assets of \$2,418,652 as of December 31, 2010 versus \$2,285,281 in total assets reported at the end of 2009. The increase in assets was largely due to significant inventory purchases at favorable terms to the Company. A posted copy of the most recent financial results is available to view on the OTC Markets website at www.otcmarkets.com.


In 2011, we have several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease. These products will allow the physician to examine organs and tissues within the body without the need for intrusive surgery. We recently announced that the Company has strengthened the current line of Laparoscopic surgical instruments in order to better align our product offerings with current global endoscopy market trends. Solos has focused its R & D efforts into the design and development of new modifications to its endoscopic instrument lines to accommodate the continual advances in Laparoscopic surgical procedures including bile duct reconstruction, laparoscopic adrenalectomy and distal pancreatectomy, amongst a host of other operations and diagnostic applications. Solos is also focused on product development as we introduced a new product line consisting of urology surgical and diagnostic instruments. The line features approximately 10 instruments, six of which are modifications to current product offerings, and five completely redesigned instruments; all of which have FDA clearance.

In addition to contributions made to the medical diagnosis and treatment for human kind, Solos has again entered the field Veterinary medicine with the launch of its revamped Veterinary Product Line of endoscopic equipment, scopes and instruments. The Solos Veterinary Product Line consists of more than 48 SKUs with prices ranging from \$75 to \$3900. According to the American Pet Product Association, in 2009, Consumers spent more than \$45 Billion on their pets, with more than \$12 Billion spent on Vet Care.

Another accomplishment that we are proud of is the recent launch of our newly designed and interactive website, www.solosendoscopy.com on Tuesday July 6, 2011. The online venue serves as a "virtual catalog" for existing and new customers and includes comprehensive information for shareholders, investors and potential partners alike. The updated look showcases streamlined navigation to allow for easy-to-use functionality, allowing users to quickly reference desired information making it easier for Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States to identify and select from Solos' vast product line. The website features a clean design with organized descriptions covering the entire scope of the Company's business and product categories. Also under development and coming soon, are links to Solos' Social Media assets including; Twitter, Facebook, LinkedIn and Stumbled Upon amongst others.

Throughout the remainder of 2011 we move forward proud with our accomplishments and energized about our potential. We have weathered numerous storms and in the process, we have continued to build our company and refine our strategy. As we pursue these goals, we remain grateful to our employees, business partners and shareholders for their ongoing support of our efforts.

Regards,



Robert H. Segersten
President and CEO

Safe Harbor Statement:

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.